Navigation Links
Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World

GLEN BURNIE, Md., May 3, 2011 /PRNewswire/ -- Answering the need for global, site-focused enrollment support, Clinical Site Services (CSS), a leader in the patient enrollment industry, announces the expansion of its services to include global enrollment planning and implementation on a local, site-centric level.

"The extension of our worldwide presence is an important step that will allow us to assist sponsors with their global patient enrollment needs," says Chris Trizna, President of Clinical Site Services. "To date, we have been quite successful in delivering patient enrollment solutions to investigative sites and sponsors in North America; this expansion means that sponsors no longer need to seek out different patient recruitment partners for North American and Rest-of-World needs."

The CSS London-based office, headed up by industry executive Richard Anderson, will tap into professionals who have more than 20 years of experience in the life science, healthcare and patient recruitment industries. They will be able to implement patient enrollment and retention campaigns which are solely based in global markets, or as an adjunct to North American endeavors.

As with all CSS North American campaigns, the global programs will offer customized clinical research support and expertise. Through Local Enrollment Specialists, regional experts who have detailed knowledge of each country's regulatory provisions, CSS will provide site assessments, chart reviews, ethics committee submissions, local patient enrollment expertise, planning and implementation in more than 40 countries.

"This is an exciting new initiative. For the first time a patient enrollment provider can support sites at local level in over 40 countries," stated Richard Anderson, CSS Director of Global Patient Enrollment. "The teams will be working with the sites to help optimize their patient enrollment programs, maximizing enrollment and ROI."

All international endeavors will be centrally managed by CSS's project team.

"It all comes down to enrollment. Generating interest is important, but it's what happens after that," shared Trizna. "Sites are the only ones who can enroll patients. Successful sites consistently meet their enrollment goals. We are poised to support them with enrollment planning and implementation."

About Clinical Site Services

Founded in 2005, Clinical Site Services (CSS) is a global enrollment performance company that increases enrollment and retention for pharma, CROs and investigative sites through a site-focused approach and adaptive enrollment process.

US Contact:
Jennifer Whitlock
VP/Director of Marketing
Clinical Site Services
P: 410-793-1067
F: 410-553-0087

UK Contact:
Richard Anderson
Director of Global Patient Enrollment
Clinical Site Services
P: +44 020 8347 9935

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Clinical Site Services
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
2. Omnicare Clinical Research Acquired by Nautic Partners, LLC
3. Stanford and SanBio Announce a Clinical Trial of Cell Therapy for Stroke Disability
4. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
5. Tissue Genesis Begins FDA-Approved Clinical Trial
6. ClearCanvas Releases First Commercial Version of Popular Clinical Radiology Workstation; PACS and RIS to Follow
7. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
8. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
9. ePharmaSolutions Launches New Application to Streamline Single Sign-On and User Account Provisioning for Sponsors Using Multiple Clinical Trial Technologies
10. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
11. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Post Your Comments:
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):